Company Overview

Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-administered polymer designed to slow CKD progression in patients with metabolic acidosis and CKD. Tricida recently completed a renal outcomes clinical trial, VALOR-CKD, to determine if veverimer slows CKD progression in patients with metabolic acidosis associated with CKD. Metabolic acidosis is a serious condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. It is estimated to pose a health risk to approximately 4.3 million patients with CKD in the United States. There are currently no therapies approved by the FDA to slow progression of kidney disease by treating chronic metabolic acidosis in patients with CKD.

Management Team
Board of Directors
Klaus Veitinger, MD, PhD
Chairman of the Board
Venture Partner OrbiMed Advisors, LLC
Robert J. Alpern, MD
Dean and Ensign Professor Yale School of Medicine
David Bonita, MD
Private Equity Partner OrbiMed Advisors, LLC
Sandra I. Coufal, MD
CEO, Toragen Biotechnologies
Kathryn Falberg
David Hirsch, MD, PhD
Managing Director Longitude Capital
Gerrit Klaerner, PhD
Chief Executive Officer & President Tricida, Inc.
Scientific and Clinical Advisory Board
David A. Bushinsky, MD
Professor of Medicine and of Pharmacology and Physiology
University of Rochester School of Medicine
Sandra I. Coufal, MD
CEO, Toragen Biotechnologies
John S. Fordtran, MD
Director of Gastrointestinal Physiology Baylor University Medical Center
Craig J. Hawker, PhD
Director Materials Research Laboratory
Professor of Chemistry, Biochemistry and Materials
University of California, Santa Barbara
Thomas H. Hostetter, MD
Professor of Medicine and Vice Chairman for Research
University of North Carolina, School of Medicine
Vandana Mathur, MD, FASN
President, Mathur Consulting
Bertram Pitt, MD
Professor of Medicine Emeritus
University of Michigan School of Medicine
Navdeep Tangri, MD, PhD, FRCP(C)
Professor of Medicine
Department of Medicine and Community Health Sciences
Scientific Director, Chronic Disease Innovation Center
University of Manitoba
Donald E. Wesson, MD, MBA
Professor of Medicine, Dell Medical School - The University of Texas at Austin
President, Donald E. Wesson Consulting, LLC
Past President, Baylor Scott & White Health and Wellness Center